CombiGene AB (publ)'s gene therapy candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy, has received patent protection in the U.S. The first application for patent protection for CG01 was filed in 2016, an international PCT application was filed in 2017 and the now granted U.S. and Russian patents last until 2037. The approvals are the first national approvals of the applications completed from the PCT application. Every year, a large number of new patients with drug-resistant focal epilepsy are diagnosed and it is this group of patients that CG01 is intended for. CombiGene currently estimates that the annual global sales potential is somewhere between USD 750 million and USD 1,500 million. The epilepsy project CG01 is in late preclinical phase and CombiGene plans to start the clinical program in the second half of 2022.